^
Association details:
| Biomarker: | STRN-ALK rearrangement |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
Published date:
01/30/2021
Excerpt:
FM-MPeM-01 PDCs were analyzed for the expression of STRN-ALK...drugs displaying selective sensitivity in FM-MPeM-01 PDC were apoptotic inhibitors (such as navitoclax and investigational compounds A-1155463 and A-1331852) and small molecule kinase inhibitors targeting MAPK signaling pathway components (pan-RAF inhibitors TAK-530, cobimetinib and trametinib)...
DOI:
https://doi.org/10.1016/j.tranon.2021.101027
